Navigation Links
Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System

NATICK, Mass., July 13 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced CE Mark for its LATITUDE(R) Patient Management system. The LATITUDE system remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient's heart health status. The system can also detect clinical events between scheduled physician visits and send relevant data directly to a patient's physician. It will be launched in Europe in a phased approach beginning this week.

"The wireless LATITUDE system will enable me to more closely monitor my patients while helping manage hospital workflow," said Konstantin M. Heinroth, M.D., Department of Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany. "I hope to provide my patients added convenience and the peace of mind that comes from knowing both their device and heart health status can be monitored."

"Boston Scientific has enrolled more than 130,000 patients on the LATITUDE system since its introduction in the U.S. in 2006, making it the most rapidly adopted remote cardiac device monitoring system in the industry(1)," said Fred Colen, President, Boston Scientific Cardiac Rhythm Management. "We expect continued success as we introduce the demonstrated benefits of our LATITUDE system to patients and physicians in Europe. Remote monitoring technology provides a significant opportunity to further improve patient care."

The LATITUDE system provides physicians actionable information that enables them to see changes in their patients' cardiac health sooner than regularly scheduled follow-up visits. LATITUDE is the only remote cardiac device monitoring system to offer a wireless weight scale and blood pressure monitor, both of which are recommended by the European Society of Cardiology for the management of Class I heart failure patients.

The international version of the LATITUDE system is compatible with the Company's wireless TELIGEN(R) implantable cardioverter defibrillator (ICD) and COGNIS(R) cardiac resynchronization therapy defibrillator (CRT-D), the world's smallest and thinnest high-energy devices.

The first enrollments of European patients onto the LATITUDE system were performed by J.H. Ruiter, M.D., Medisch Centrum Alkmaar, Alkmaar, The Netherlands, and Peter Mortensen, M.D., Chief Physician, SkejbyUniversityHospital, Aarhus, Denmark.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth investment. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

(1) Data based on number of patients at three years post-launch. Data on file.

    CONTACT:        David Knutson
                    651-582-6574 (office)
                    651-260-8288 (mobile)
                    Media Relations
                    Boston Scientific Corporation

                    Larry Neumann
                    508-650-8696 (office)
                    Investor Relations
                    Boston Scientific Corporation

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific to Participate in Wachovia Conference
2. Boston Scientifics SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)
3. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
4. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Boston Scientific Welcomes Launch of Syntax Score Website
7. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
8. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
9. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
10. Xconomy Launches XSITE 2009; First Annual Xconomy Summit on Innovation, Technology, and Entrepreneurship at Boston University
11. UMass Boston Opens Venture Development Center to Expand R&D Activity
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... ) The integration ... security to access and transact across channels. Using ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):